Guerbet and Jubilant Draximage Inc (JDI) have decided to end their partnership for the distribution of JDI’s nuclear medicine products in Europe.
09/02/2012 2011 revenue
Strong and steady growth driven by Dotarem and Lipiodol
The Guerbet Group, specialized in contrast agents for medical imaging, is to invest €31 million in its three French production sites: €16.6 million at Aulnay-sous-Bois in the Seine-Saint-Denis department; €10.7 million at Lanester in the Morbihan department and €3.8 million at Marans in the...
17/01/2012 Guerbet at ECR 2012
Guerbet is participating in the ECR from March 1st to 5th in Vienna (Austria).